Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NYSEAMERICAN:AZTR NASDAQ:NCEL OTCMKTS:OTLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAZTRAzitra$0.25+0.7%$0.21$0.10▼$2.40$4.03M-1.49.22 million shs326,065 shsNCELNLS Pharmaceutics$3.62+0.8%$2.78$1.83▼$30.80$19.35M1.0182,325 shs12,168 shsOTLCOncotelic Therapeutics$0.04+2.1%$0.04$0.02▼$0.11$17.30M-0.54276,422 shs15,250 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%AZTRAzitra-0.40%-0.97%+5.03%+7.09%-87.91%NCELNLS Pharmaceutics-6.75%+7.16%+58.85%+32.47%-79.01%OTLCOncotelic Therapeutics+1.33%+6.11%-1.80%-47.02%-32.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAZTRAzitra$0.25+0.7%$0.21$0.10▼$2.40$4.03M-1.49.22 million shs326,065 shsNCELNLS Pharmaceutics$3.62+0.8%$2.78$1.83▼$30.80$19.35M1.0182,325 shs12,168 shsOTLCOncotelic Therapeutics$0.04+2.1%$0.04$0.02▼$0.11$17.30M-0.54276,422 shs15,250 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%AZTRAzitra-0.40%-0.97%+5.03%+7.09%-87.91%NCELNLS Pharmaceutics-6.75%+7.16%+58.85%+32.47%-79.01%OTLCOncotelic Therapeutics+1.33%+6.11%-1.80%-47.02%-32.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.75Reduce$1.251,113.59% UpsideAZTRAzitra 3.00Buy$4.001,512.90% UpsideNCELNLS Pharmaceutics 1.00SellN/AN/AOTLCOncotelic Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21AZTRAzitra$10K401.51N/AN/A$0.35 per share0.71NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/AOTLCOncotelic Therapeutics$70K247.08$0.56 per share0.07$0.59 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/AAZTRAzitra-$10.95MN/AN/AN/AN/AN/A-344.58%-228.36%5/12/2026 (Estimated)NCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/AOTLCOncotelic Therapeutics$249.28M$0.590.07N/AN/AN/A350.62%210.10%N/ALatest AZTR, APLT, OTLC, and NCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026N/AAZTRAzitra-$0.01N/AN/AN/AN/AN/A4/15/2026Q4 2025OTLCOncotelic TherapeuticsN/A$0.59N/A$0.59N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96AZTRAzitraN/A2.832.83NCELNLS PharmaceuticsN/A0.760.76OTLCOncotelic Therapeutics0.010.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%AZTRAzitra11.16%NCELNLS PharmaceuticsN/AOTLCOncotelic TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%AZTRAzitra0.10%NCELNLS Pharmaceutics16.40%OTLCOncotelic Therapeutics39.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableAZTRAzitra1016.19 million16.18 millionNot OptionableNCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableOTLCOncotelic Therapeutics20443.48 million269.55 millionNot OptionableAZTR, APLT, OTLC, and NCEL HeadlinesRecent News About These CompaniesOncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease2 hours ago | globenewswire.comOncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific AbstractsApril 30, 2026 | globenewswire.comNetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development PathwaysApril 24, 2026 | globenewswire.comOncotelic Therapeutics Provides Corporate Update on Partnership StrategyApril 24, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on EvaluationApril 23, 2026 | globenewswire.comAdvancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial RecognitionApril 22, 2026 | thespec.comTOncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation EvolutionApril 21, 2026 | globenewswire.comOncotelic Therapeutics, Inc.: Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline ProgressApril 16, 2026 | finanznachrichten.deOncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline ProgressApril 16, 2026 | financialpost.comFOncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline ProgressApril 16, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance SpaceApril 10, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,April 8, 2026 | globenewswire.comAI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory StandardsApril 7, 2026 | markets.businessinsider.comOncotelic forms AI-driven robotics partnership for GMP automationApril 2, 2026 | tipranks.comOncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics PlatformApril 2, 2026 | financialpost.comFOncotelic Therapeutics Delays Annual 10-K FilingMarch 31, 2026 | tipranks.comOncotelic Subsidiary Showcases Deciparticle Platform at BIO-EuropeMarch 30, 2026 | tipranks.comSapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026March 24, 2026 | globenewswire.comSapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual MeetingMarch 23, 2026 | globenewswire.comNetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage PortfoliosFebruary 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZTR, APLT, OTLC, and NCEL Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 05/4/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Azitra NYSEAMERICAN:AZTR$0.25 +0.00 (+0.69%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.NLS Pharmaceutics NASDAQ:NCEL$3.62 +0.03 (+0.84%) As of 10:36 AM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Oncotelic Therapeutics OTCMKTS:OTLC$0.04 +0.00 (+2.09%) As of 10:07 AM EasternOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
